Clinical Trial Update: CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating CD22 CAR T-cells to extend remission after CD19 CAR T-cell therapy in children, adolescents, and adults with relapsed/refracto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CD19 CAR-T cell therapy (CAR-T cell therapy targeting CD19)
• CD22 CAR T-cell therapy (CD22-directed chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Lymphoblastic Leukemia, B-All | Phase 2 | Status: NOT_YET_RECRUITING